D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO)

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $31.00 price objective on the stock.

CRVO has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of CervoMed in a report on Thursday, December 18th. Brookline Capital Acquisition upgraded CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Zacks Research raised CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Cantor Fitzgerald assumed coverage on CervoMed in a research note on Thursday, December 18th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CervoMed has a consensus rating of “Moderate Buy” and an average target price of $22.17.

CervoMed Trading Down 0.2%

Shares of NASDAQ:CRVO opened at $4.01 on Wednesday. The stock has a market cap of $37.10 million, a PE ratio of -1.38 and a beta of -0.77. The stock’s fifty day simple moving average is $5.90 and its two-hundred day simple moving average is $7.54. CervoMed has a 1-year low of $1.92 and a 1-year high of $16.94.

Institutional Trading of CervoMed

A number of large investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the period. XTX Topco Ltd purchased a new stake in shares of CervoMed in the fourth quarter worth about $81,000. Jane Street Group LLC bought a new position in shares of CervoMed in the fourth quarter valued at approximately $88,000. GSA Capital Partners LLP purchased a new position in CervoMed during the third quarter valued at approximately $91,000. Finally, Marshall Wace LLP purchased a new position in CervoMed during the second quarter valued at approximately $76,000. 25.15% of the stock is owned by hedge funds and other institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.